BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18448758)

  • 1. BRCA screening.
    Obstet Gynecol; 2008 May; 111(5):1205-6. PubMed ID: 18448758
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
    Wolff TA; Wilson JE
    Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimal selection of individuals for BRCA mutation testing.
    Evans DG; Lalloo F; Eccles D
    J Clin Oncol; 2006 Jul; 24(20):3311; author reply 3311-2. PubMed ID: 16829657
    [No Abstract]   [Full Text] [Related]  

  • 4. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
    Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
    Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers.
    James PA; Harris M; Lindeman GJ; Mitchell G
    J Med Genet; 2008 Nov; 45(11):765-6. PubMed ID: 18978334
    [No Abstract]   [Full Text] [Related]  

  • 6. Pros and cons of screening for BRCA mutations.
    Howard-McNatt M
    N C Med J; 2013; 74(6):489-90. PubMed ID: 24316772
    [No Abstract]   [Full Text] [Related]  

  • 7. One risk fits all?
    De Bock GH; Mourits MJ; Oosterwijk JC
    J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
    [No Abstract]   [Full Text] [Related]  

  • 8. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
    Olopade OI
    Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
    [No Abstract]   [Full Text] [Related]  

  • 9. No association of miscarriage and BRCA carrier status in Pakistani breast/ovarian cancer patients with a history of parental consanguinity.
    Rashid MU; Torres D; Rasheed F; Sultan F; Shakoori AR; Amin A; Schlaefer K; Hamann U
    Breast Cancer Res Treat; 2009 Jul; 116(1):211-3. PubMed ID: 18574689
    [No Abstract]   [Full Text] [Related]  

  • 10. BRCA testing: ethics lessons for the new genetics.
    Sherwin S
    Clin Invest Med; 2004 Feb; 27(1):19-22. PubMed ID: 15061582
    [No Abstract]   [Full Text] [Related]  

  • 11. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogenic loss of BRCA in breast cancer: the "two-hit" hypothesis takes a hit.
    Meric-Bernstam F
    Ann Surg Oncol; 2007 Sep; 14(9):2428-9. PubMed ID: 17406948
    [No Abstract]   [Full Text] [Related]  

  • 13. Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?
    Capalbo C; Buffone A; Vestri A; Ricevuto E; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    J Clin Oncol; 2007 Jun; 25(18):2632-4; author reply 2634-5. PubMed ID: 17577048
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular and in silico analysis of BRCA1 and BRCA2 variants.
    Tommasi S; Pilato B; Pinto R; Monaco A; Bruno M; Campana M; Digennaro M; Schittulli F; Lacalamita R; Paradiso A
    Mutat Res; 2008 Sep; 644(1-2):64-70. PubMed ID: 18694767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
    Maheu C; Thorne S
    Res Nurs Health; 2008 Dec; 31(6):553-62. PubMed ID: 18449940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort.
    Fortuny D; Balmaña J; Graña B; Torres A; Ramón y Cajal T; Darder E; Gadea N; Velasco A; López C; Sanz J; Alonso C; Brunet J
    Hum Reprod; 2009 Apr; 24(4):1000-6. PubMed ID: 19112076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary breast and ovarian cancer syndrome.
    ACOG Committee on Practice Bulletins
    Gynecol Oncol; 2009 Apr; 113(1):6-11. PubMed ID: 19309638
    [No Abstract]   [Full Text] [Related]  

  • 19. Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing?
    Doksum T; Bernhardt BA; Holtzman NA
    Genet Med; 2003; 5(2):99-105. PubMed ID: 12644779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.